There is data, data everywhere with layers of blockchain, data analytics and cybersecurity features. Consequently, tracking and tracing biological systems data and processes are an increasingly important part of medical device and biopharmaceutical discovery, design, development, commercialization and post launch surveillance as well as basic science research. The benefits include complying with regulatory mandates, improving the security of the data, intellectual property protection, synchronization of large data sets, accurately timing electronic transfers of data, improving artificial intelligence algorithms and more.

Here is how one hospital system is tracking data.

A 2008 conference highlighted the challenges in agriculture, bioenergy, biopharmaceutical manufacturing, and medicine and, in the following 10 years, there are still substantial gaps in fulfilling the agenda.

Other traceability applications include:

  1. Cannabis traceability
  2. Food systems
  3. Software standards compliance and traceability
  4. Connecting Requirements to IP: Achieving Requirements
  5. Intellectual property traceability and counterfeiting

6. Traceability and the internet of (medical) things

7. Traceability and artificial intelligence

8. Supply chain tracking and tracing

9. Big data traceability and lineage

10. Tracking the impact of research data

As the 4th industrial revolution proceeds, traceability in many industries, including bioscience and medicine, will become increasingly important if we are reach our goals of using data to improve quality , reduce costs, protect confidentiality, conform to regulatory mandates and improve the doctor and patient experience.

arlen meyersBy Arlen Meyers, MD, MBA is the President and CEO of the Society of Physician Entrepreneurs.

Arlen Meyers is a professor emeritus of otolaryngology, dentistry, and engineering at the University of Colorado School of Medicine and the Colorado School of Public Health and President and CEO of the Society of Physician Entrepreneurs at . He has created several medical device and digital health companies. Most of them failed. His primary research centers around biomedical and health innovation and entrepreneurship and life science technology commercialization.

He consults for and speaks to companies, governments, colleges and universities around the world who need his expertise and contacts in the areas of bio entrepreneurship, bioscience, healthcare, healthcare IT, medical tourism — nationally and internationally, new product development, product design, and financing new ventures.

And Lisa Schilling, MD, MSPH, is a Professor of Medicine at the University of Colorado School of Medicine.